Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 3
2(40.0%)
5Total
Phase 2(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06529718Phase 2Recruiting

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Role: collaborator

NCT05615818Phase 3Recruiting

Personalized Medicine for Advanced Biliary Cancer Patients

Role: collaborator

NCT05472259Phase 2Recruiting

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

Role: lead

NCT04257461Phase 3Active Not Recruiting

A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

Role: lead

NCT05083247Phase 2Recruiting

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Role: collaborator

All 5 trials loaded